Suppr超能文献

在接受抑郁和焦虑治疗的患者中,健康状况的 EQ-5D 变化的反应性。

Responsiveness to change in health status of the EQ-5D in patients treated for depression and anxiety.

机构信息

Division of Mental Health and Substance Abuse, Diakonhjemmet Hospital, Postboks 23 Vinderen, Oslo, 0319, Norway.

Department of Psychology, Norwegian University of Science and Technology, Trondheim, NO-7491, Norway.

出版信息

Health Qual Life Outcomes. 2023 Apr 15;21(1):35. doi: 10.1186/s12955-023-02116-y.

Abstract

BACKGROUND

The EQ-5D is a commonly used generic measure of health but evidence on its responsiveness to change in mental health is limited. This study aimed to explore the responsiveness of the five-level version of the instrument, the EQ-5D-5 L, in patients receiving treatment for depression and anxiety.

METHODS

Patient data (N = 416) were collected at baseline and at end of treatment in an observational study in a Norwegian outpatient clinic. Patients were adults of working age (18-69 years) and received protocol-based metacognitive or cognitive therapy for depression or anxiety according to diagnosis. Responsiveness in the EQ-5D was compared to change in the Beck Depression Inventory-II (BDI-II) and the Beck Anxiety Inventory (BAI). Effect sizes (Cohen's d), Standardised response mean (SRM), and Pearson's correlation were calculated. Patients were classified as "Recovered", "Improved", or "Unchanged" during treatment using the BDI-II and the BAI. ROC analyses determined whether the EQ-5D could correctly classify patient outcomes.

RESULTS

Effect sizes were large for the BAI, the BDI-II, the EQ-5D value and the EQ VAS, ranging from d = 1.07 to d = 1.84. SRM were also large (0.93-1.67). Pearson's correlation showed strong agreement between change scores of the EQ-5D value and the BDI-II (r -0.54) and moderate between the EQ-5D value and the BAI (r -0.43). The EQ-5D consistently identified "Recovered" patients versus "Improved" or "Unchanged" in the ROC analyses with AUROC ranging from 0.72 to 0.84.

CONCLUSION

The EQ-5D showed good agreement with self-reported symptom change in depression and anxiety, and correctly identified recovered patients. These findings indicate that the EQ-5D may be appropriately responsive to change in patients with depression and anxiety disorders, although replication in other clinical samples is needed.

摘要

背景

EQ-5D 是一种常用的通用健康衡量标准,但关于其在心理健康方面变化的反应性的证据有限。本研究旨在探讨该工具的五维版本,即 EQ-5D-5L,在接受抑郁和焦虑治疗的患者中的反应性。

方法

在挪威一家门诊诊所的观察性研究中,在基线和治疗结束时收集了患者数据(N=416)。患者为 18-69 岁的成年工作年龄人群,根据诊断接受基于认知疗法或元认知疗法的协议治疗。EQ-5D 的反应性与贝克抑郁量表第二版(BDI-II)和贝克焦虑量表(BAI)的变化进行了比较。计算了效应大小(Cohen's d)、标准化反应均值(SRM)和 Pearson 相关系数。使用 BDI-II 和 BAI,将治疗期间的患者分为“康复”、“改善”或“无变化”。ROC 分析确定 EQ-5D 是否能够正确分类患者的结果。

结果

BAI、BDI-II、EQ-5D 值和 EQ VAS 的效应大小较大,范围从 d=1.07 到 d=1.84。SRM 也较大(0.93-1.67)。Pearson 相关系数显示 EQ-5D 值与 BDI-II 的变化评分之间具有很强的一致性(r=-0.54),与 BAI 的变化评分之间具有中度一致性(r=-0.43)。在 ROC 分析中,EQ-5D 始终能够将“康复”患者与“改善”或“无变化”患者区分开来,AUROC 范围从 0.72 到 0.84。

结论

EQ-5D 与抑郁和焦虑的自我报告症状变化具有良好的一致性,并且能够正确识别康复患者。这些发现表明,EQ-5D 可能适当响应抑郁和焦虑障碍患者的变化,尽管需要在其他临床样本中进行复制。

相似文献

1
Responsiveness to change in health status of the EQ-5D in patients treated for depression and anxiety.
Health Qual Life Outcomes. 2023 Apr 15;21(1):35. doi: 10.1186/s12955-023-02116-y.
2
Responsiveness of the anxiety/depression dimension of the 3- and 5-level versions of the EQ-5D in assessing mental health.
Qual Life Res. 2018 Jun;27(6):1625-1633. doi: 10.1007/s11136-018-1828-1. Epub 2018 Mar 7.
3
Self-Reported Health in Patients on or at Risk of Sick Leave Due to Depression and Anxiety: Validity of the EQ-5D.
Front Psychol. 2021 Oct 28;12:655151. doi: 10.3389/fpsyg.2021.655151. eCollection 2021.
7
Psychometric assessment of EQ-5D-5L and ReQoL measures in patients with anxiety and depression: construct validity and responsiveness.
Qual Life Res. 2021 Sep;30(9):2633-2647. doi: 10.1007/s11136-021-02833-1. Epub 2021 Apr 9.

引用本文的文献

1
Quality of life and financial implications of depression in India.
Indian J Psychiatry. 2025 Jul;67(7):675-684. doi: 10.4103/indianjpsychiatry_170_25. Epub 2025 Jul 15.
4
Exploring the Characteristics of Gut Microbiota Associated with Depression via the Depression Assessment Scales.
J Microbiol Biotechnol. 2024 Nov 27;35:e2408042. doi: 10.4014/jmb.2408.08042.

本文引用的文献

1
Screening for Anxiety and Depressive Symptoms in Type 2 Diabetes Using Patient-Reported Outcome Measures: Comparative Performance of the EQ-5D-5L and SF-12v2.
MDM Policy Pract. 2018 Sep 15;3(2):2381468318799361. doi: 10.1177/2381468318799361. eCollection 2018 Jul-Dec.
2
Self-Reported Health in Patients on or at Risk of Sick Leave Due to Depression and Anxiety: Validity of the EQ-5D.
Front Psychol. 2021 Oct 28;12:655151. doi: 10.3389/fpsyg.2021.655151. eCollection 2021.
4
Psychometric properties of the EQ-5D-5L: a systematic review of the literature.
Qual Life Res. 2021 Mar;30(3):647-673. doi: 10.1007/s11136-020-02688-y. Epub 2020 Dec 7.
6
Filling the psycho-social gap in the EQ-5D: the empirical support for four bolt-on dimensions.
Qual Life Res. 2020 Nov;29(11):3119-3129. doi: 10.1007/s11136-020-02576-5. Epub 2020 Jul 9.
9
Targets and outcomes of psychotherapies for mental disorders: an overview.
World Psychiatry. 2019 Oct;18(3):276-285. doi: 10.1002/wps.20661.
10
General population norms for the EQ-5D-3 L in Norway: comparison of postal and web surveys.
Health Qual Life Outcomes. 2018 Oct 19;16(1):204. doi: 10.1186/s12955-018-1029-1.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验